Barclays initiated coverage of Ideaya Biosciences (IDYA) with an Overweight rating and $40 price target The firm sees two “value-inflecting” data readouts from the company by the end of 2025: the Phase 1 data for DLL3 antibody-drug conjugate in small cell lung cancer and the pivotal data for darovasertib plus crizotinib in uveal melanoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Hold Rating for IDEAYA Biosciences Amid Favorable Financial Terms and Developmental Risks
- Ideaya Biosciences price target raised to $74 from $72 at JPMorgan
- Ideaya Biosciences submits IDE892 IND application to FDA
- IDEAYA Biosciences: Strategic Partnership with Servier Bolsters Financial Outlook and Validates Darovasertib Potential
- IDEAYA Biosciences: Strategic Partnerships and Financial Strength Underpin Buy Rating